Skip to main content

Day: October 29, 2021

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction

FREEDOM-2 trial will evaluate the potential for the company’s investigational allogeneic cell therapy, FCR001, to induce durable immune tolerance in patients who have previously received a kidney from a living donor BOSTON, Oct. 29, 2021 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the initiation of the company’s Phase 2 FREEDOM-2 study. Northwestern University is the first FREEDOM-2 clinical site to have been activated and has now begun screening for eligible patients. Additional sites are expected to be activated in 2022. This trial will explore...

Continue reading

Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update

BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results and provide a business update on Wednesday, November 10, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Conference ID: CYCCQ321         US call: (877) 876-9173/ international call: +1 (785) 424-1667  Replay: US: (800) 938-2795 / international archive: +1 (402) 220-9029 Code for live and replay conference call is CYCCQ321 Webcast link. For the live and replay webcast, please visit the Corporate Presentations page on the Cyclacel website...

Continue reading

Acron Announces Extraordinary General Meeting

29 October 2021   Acron Announces Extraordinary General Meeting   Acron Board of Directors resolved to convene an extraordinary general meeting as an absentee vote on 3 December 2021.   In accordance with the approved agenda, the general meeting is to consider the following matters:Paying (distributing) dividends for 9M 2021 Making amendments to Acron Charter Approving the Regulation on Acron Board of Directors as amended.The Board of Directors’ recommendations on the dividend amount and record date will be considered and disclosed on or before 12 November 2021.   The record date for attending the general meeting is 9 November 2021 (close of business).  Media Contacts Sergey Dorofeev Anastasiya Gromova Tatiana Smirnova Public Relations Phone: +7 (495) 777-08-65 (ext. 5196) Investor Contacts Ilya Popov Sergey Smirnov Strategy and...

Continue reading

Stantec amends and extends existing credit facilities under sustainability-linked loan; becomes first company globally to link financing to Bloomberg Gender Equality Index score

EDMONTON, Alberta, Oct. 29, 2021 (GLOBE NEWSWIRE) — Stantec (TSX, NYSE: STN), a global leader in sustainable design and engineering, today announced that it has completed an agreement to amend and extend its existing $1.1 billion syndicated senior credit facilities (the “Credit Facilities”). Pursuant to the amendment, the maturity date for the $800 million revolving credit facility and the $160 million term loan tranche has been extended to October 29, 2026, and the maturity date for the $150 million term loan tranche has been extended to October 29, 2024. The Credit Facilities are structured as a sustainability-linked loan (“SLL”), aligning Stantec’s financing strategy with its continued commitment towards environmental, social and governance (“ESG”) leadership. The SLL has an interest rate incentive mechanism that aligns the...

Continue reading

Offer for Subscription and Publication of Prospectus

Seneca Growth Capital VCT PlcLEI: 213800VP9N3LOQZ22441Publication of a Prospectus 29 October 2021 SENECA GROWTH CAPITAL VCT PLC(the “Company”) Offer for Subscription The Board of Seneca Growth Capital VCT Plc is pleased to announce that the Company has published a prospectus in relation to an offer for subscription for B ordinary shares of 1p each in the Company to raise, in aggregate, up to £10 million with an over-allotment facility of up to a further £10 million (before issue costs) (the “Offer”). The Offer will open on 29 October 2021 and is expected to close no later than 5.00 p.m. on 5 April 2022 in relation to the tax year 2021/22 and will close at 5.00 p.m. on 26 October 2022 in relation to the tax year 2022/23 (unless, in either case, the Offer has been fully subscribed before these dates or closed earlier at the discretion...

Continue reading

On the final termination of legal proceedings related to the mandatory repurchase offer of AS “Olainfarm”

The Supreme Court has rejected an ancillary complaint by the minority shareholders of AS Olainfarm regarding the decision of the Administrative District Court of 24 August 2021, which completely terminated the legal proceedings initiated in relation to the application of two minority shareholders of AS Olainfarm to annul the decision of the Finance and Capital Market Commission (FCMC), by which the FCMC allowed AS AB CITY to make a mandatory share repurchase offer for AS Olainfarm shares. The Supreme Court decided to upheld the decision of the Administrative District Court of 24 August 2021 on termination of the proceedings in the administrative case, determining that the minority shareholders of AS Olainfarm did not have the subjective public right to apply to the court with such a claim. The decision of the Supreme Court is final and...

Continue reading

Chindata Group holds strategic dialogue with the Climate Group

BEIJING, Oct. 29, 2021 (GLOBE NEWSWIRE) — Alex Ju, Founder and CEO of Chindata Group held a strategic dialogue with Helen Clarkson, CEO of the Climate Group on October 28. They exchanged in-depth views on a range of topics including the importance of digital infrastructure in supporting global growth, the role of internet technology companies in reducing carbon emissions, as well as the upcoming 2021 United Nations Climate Change Conference (COP26). On behalf of the Climate Group, Helen Clarkson not only congratulated Chindata Group on joining the RE100 initiative, but also recognized its unwavering efforts in utilizing zero-carbon computing power and the commitment to Asia Pacific emerging markets. At the same time, Mr. Ju acknowledged the Climate Group’s long-term efforts in encouraging global businesses and governments...

Continue reading

The UroLift® System Receives Bronze Award for Best New Branded Television Campaign and Honorable Mention in the Best Branded Website Category from DTC Perspectives

WAYNE, Pa., Oct. 29, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that the UroLift® System was honored by DTC Perspectives with a Bronze Award in the “Best New Branded Television Campaign” category and an Honorable Mention in the “Best Branded Website” category. The National Advertising Awards were announced at the Annual DTC National Conference in Boston, which was held October 12-14. The campaign, “Theater ‘Flow’,” is the first national TV campaign in Teleflex history. The ad features prominent imagery associated with symptoms of enlarged prostate, or benign prostatic hyperplasia (BPH), including increased frequency, a weak urine stream and feeling of incomplete emptying of the bladder. The ad includes a clear call to action to visit the branded website and to call a toll-free number. The UroLift...

Continue reading

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release third quarter 2021 results on Wednesday, November 10, 2021, and host a conference call at 8:30 a.m. EST to discuss financial results and recent corporate developments. The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 6166004 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call...

Continue reading

Verkkokauppa.com Oyj – Managers’ Transactions – Seppo Niemelä

Verkkokauppa.com Oyj MANAGERS’ TRANSACTIONS 29 October 2021 at 13:30 EEST Verkkokauppa.com Oyj – Managers’ Transactions – Seppo Niemelä Transaction notification under Article 19 of EU Market Abuse Regulation. Verkkokauppa.com Oyj has received a notification from Seppo Niemelä, Verkkokauppa.com Oyj’s management team member, of a transaction made with Verkkokauppa.com Oyj’s financial instrument, according to the Article 19 of EU Market Abuse Regulation. Detailed information about the transaction is given here under.____________________________________________Person subject to the notification requirementName: Seppo NiemeläPosition: Other senior manager Issuer: Verkkokauppa.com OyjLEI: 743700QZE6B52SHHTV75Notification type: INITIAL NOTIFICATIONReference number: 6223/4/4____________________________________________ Transaction...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.